A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)
The purpose of this study is to assess the safety and efficacy of ABT-493/ABT-530 following 12 weeks of treatment in adults with chronic Hepatitis C Virus Infection genotype 1, 2, 4, 5 or 6 infection and compensated cirrhosis.
Study Type: Interventional
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)
Enrollment: 146
Study Start Date: December 2015
Study Completion Date: January 2017
Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms:
- Experimental: ABT-493/ABT-530
| Category | Value |
|---|---|
| Date last updated at source | 2017-02-10 |
| Study type(s) | Interventional |
| Expected enrolment | 146 |
| Study start date | 2015-12-01 |
| Estimated primary completion date | 2016-10-01 |